Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fuster, V.
Right arrow Articles by Badimon, J.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fuster, V.
Right arrow Articles by Badimon, J.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Understanding the pathophysiology of the arterial wall: which method should we choose? Magnetic resonance imaging

V. Fuster*, R. Corti, Z.A. Fayad and J.J. Badimon

Mount Sinai Medical Center New York, U.S.A

* Correspondence: Professor Valentin Foster, Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1030, New York, NY 10029, U.S.A.

Abstract

It has become increasingly recognized that it is the composition of plaque rather than the degree of stenosis that determines risk for plaque disruption, and therefore patient outcome. Magnetic resonance imaging (MRI) is the most promising method for imaging plaque non-invasively and determining different plaque components. It allows discrimination of lipid core, fibrosis, calcification and thrombus deposits. It can be used to study the progression of and the effects of treatment for cardiovascular disease (e.g. statin therapy) over time. MRI can also be used to assess accurately the activity of thrombi and determine when they become inactive. MRI technology is evolving rapidly and will open up new areas for diagnosis, treatment and prevention of atherosclerosis.

Key Words: Atherosclerosis • magnetic resonance imaging • plaque composition

References

  1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242–250[Web of Science][Medline]
  2. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126–2146[Abstract/Free Full Text]
  3. Shah PK, Forrester JS. Pathophysiology of acute coronary syndromes. Am J Cardiol. 1991;68:16C–23C[Medline]
  4. Falk E, Shah PK, Fustcr V. Coronary plaque disruption. Circulation. 1995;92:657–671[Free Full Text]
  5. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999;353(suppl 2):SII5–SII9
  6. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol. 1993;22:1141–1154[Abstract]
  7. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56–62[Abstract]
  8. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157–1166[Abstract/Free Full Text]
  9. Nobuyoshi M, Tanaka M, Nosaka H, et al. Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol. 1991;18:904–910[Abstract]
  10. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992;69:729–732[CrossRef][Web of Science][Medline]
  11. Glagov S, Weiscnberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375[Abstract]
  12. Fayad ZA, Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. Ann N Y Acad Sci. 2000;902:173–186[Web of Science][Medline]
  13. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Cire Res. 2001;89:305–316
  14. Shinnar M, Fallon JT, Wehrli S, et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vase Biol. 1999;19:2756–2761
  15. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombosic components of human atherosclerosis in vivo. Circulation. 1996;94:932–938[Abstract/Free Full Text]
  16. Fayad ZA, Nahar T, Fallon JT, et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation. 2000;101:2503–2509[Abstract/Free Full Text]
  17. Skinner MP, Yuan C, Mitsumori L, et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med. 1995;1:69–73[CrossRef][Web of Science][Medline]
  18. Fayad ZA, Fallon JT, Shinnar M, et al. Noninvasive In vivo highresolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation. 1998;98:1541–1547[Abstract/Free Full Text]
  19. Worthley SG, Helft G, Fuster V, et al. Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. Circulation. 2000;101:2956–2961[Abstract/Free Full Text]
  20. Fayad ZA, Fuster V, Fallon JT, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000;102:506–510[Abstract/Free Full Text]
  21. Botnar RM, Stuber M, Kissinger KV, Kim WY, Spuentrup E, Manning WJ. Noninvasive coronary vessel wall and plaque imaging with magnetic resonance imaging. Circulation. 2000;102:2582–2587[Abstract/Free Full Text]
  22. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249–252[Abstract/Free Full Text]
  23. Fuster V, Fallon IT, Nemerson Y. Coronary thrombosis. Lancet. 1996;348(suppl 1):S7–S10
  24. Kaikita K, Ogawa H, Yasue H, et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol. 1997;17:2232–2237[Abstract/Free Full Text]
  25. Drew AF, Davenport P, Apostolopoulos J, Tipping PG. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest. 1997;77:291–298[Web of Science][Medline]
  26. Lauffer RB, Graham PB, Lahti KM, Nair S, Caravan P, Kolodziej A. Direct clot detection with MRI using a novel fibrin-targeted gadolinium agent. Circulation. 2000;102:II–375
  27. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001;104:1280–1285[Abstract/Free Full Text]
  28. Corti R, Osende JI, Fuster V, Fayad ZA, Fallon JT, Badimon JJ. Artery dissection and arterial thrombus aging: the role of noninvasive magnetic resonance imaging. Circulation. 2001;103:2420–2421[Free Full Text]
  29. Corti R, Osende JI, Fayad ZA, Fallon JT, Fustcr V, Mizsei G, Dickstein E, Drayer B, Badimon JJ. In vivo noninvasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol. 2002;39:1366–1373[Abstract/Free Full Text]
  30. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981–993[Free Full Text]
  31. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost. 1995;74:552–559[Web of Science][Medline]
  32. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Cire Res. 1995;76:412–417
  33. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277–2283[Web of Science][Medline]
  34. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164–2170[Abstract/Free Full Text]
  35. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three dimensional intravascular ultrasound study. Circulation. 2001;103:192–195[Abstract/Free Full Text]
  36. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA. New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. Ann N Y Acad Sci. 2001;947:181–195[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fuster, V.
Right arrow Articles by Badimon, J.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fuster, V.
Right arrow Articles by Badimon, J.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?